Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 8,773-8,784 of 23,847
Drug study icon
CompletedNCT03257865

A study to Assess Brexpiprazole Versus Placebo for Acute manic episodes, Associated With Bipolarity type I

This study is completed in the United States, in Croatia, and in Ukraine. It focuses on manic episodes in bipolarity type I.

Multiple locations, including Little Rock
BipolarityDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
United States, Croatia, Ukraine
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity
Drug study icon
CompletedNCT07314333

A study to Assess How Centanafadine Interacts With Stimulants in the Body

This study is looking at whether a digital support tool can help people with Adhd. Participants receive a study treatment and complete follow-up visits and assessments.

In Salt Lake City
ADHDDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
ADHD
Drug study icon
CompletedNCT02282761

A study to Assess the Antipsychotic Efficacy of ITI-007

This study exists to compare options and see whether the medication ITI-007 offers something meaningfully different. Researchers are trying to understand what the medication ITI-007 could change in day-to-day care and decision-making.

Multiple locations, including Little Rock
SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT02469155

A study to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

This study exists to compare options and see whether the medication ITI-007 offers something meaningfully different. Researchers are trying to understand what the medication ITI-007 could change in day-to-day care and decision-making.

Multiple locations, including Little Rock
SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT04398225

A study to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

This study exists to better understand the safety of this type of care and how manageable it feels in practice. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.

In Hollywood
ADHDDrugFrom 4 Years to 12 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
ADHD
Drug study icon
CompletedNCT03605836

A study Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

This study exists to understand whether a medication treatment is both safe enough and useful enough to take further. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.

In Orlando
ADHDDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
ADHD
Drug study icon
CompletedNCT03287869

Brexpiprazole for Bipolarity

This study is completed in the United States, in Bulgaria, in Croatia, .... It is testing brexpiprazole for Bipolarity.

Multiple locations, including Little Rock
BipolarityDrugFrom 18 Years to 65 Years
Countries
United States, Bulgaria, Croatia, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity
Drug study icon
CompletedNCT03568500

A study to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

This study is completed in the United Kingdom. It focuses on schizophrenia.

Multiple locations, including Chertsey
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United Kingdom
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.